{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-005648","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2025-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.502376+00:00","generated_at":"2026-05-27T13:43:00.458711+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"SELLAS announces positive interim analysis for Phase 3 REGAL trial of GPS in AML; IDMC recommends continuation","bullets":["IDMC recommended continuation of Phase 3 REGAL trial after interim analysis triggered by 60 deaths; no safety concerns.","Blinded data: fewer than 50% of patients deceased after median follow-up of 13.5 months; pooled median survival >13.5 months vs ~6 months historical.","Blinded immune response: 80% of GPS patients showed GPS-specific T-cell response, exceeding prior Phase 2 result of 64%.","Next final analysis planned at 80 events, expected in 2025; company preparing BLA submission."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-005648","json":"https://secwatch.observer/filing/0001104659-25-005648.json","markdown":"https://secwatch.observer/filing/0001104659-25-005648.md","text":"https://secwatch.observer/filing/0001104659-25-005648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/0001104659-25-005648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000110465925005648/tm254291d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T13:43:00.458711+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}